Adial Pharmaceuticals ADILW 深 沪
等待开盘 08-27 09:30:00 美东时间
0.0009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 总市值 1.58万
- 52周最高 0.199
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 总股本 1750.35万
- 历史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On August 19, 2026, ...
08-26 04:57
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
The latest announcement is out from Adial Pharmaceuticals ( ($ADIL) ). On Augus...
08-22 06:02
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
08-18 00:39
Adial Pharmaceuticals Plans Major Leadership and Board Transition
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. As of ...
08-14 05:43
Adial Pharmaceuticals Completes Azora Merger, Shifts Strategic Focus
Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On June 11, 2026, Adial...
06-12 00:57
Adial Pharmaceuticals Acquires Azora Therapeutics In All-Stock Transaction, Enters Concurrent Private Placement To Raise Up To $64M
About the Transactions The acquisition of Azora was structured as an asset acquisition pursuant to which all of Azora's outstanding equity interests were exchanged, based on a fixed exchange ratio, for a combination of 437,474 shares of Adial common stock and approximately 12,930 shares of Adial Ser...
06-11 23:51
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals acquired Azora Therapeutics, gaining its lead asset AT177, an oral, colon-targeted AhR agonist for ulcerative colitis designed to minimize systemic exposure. Concurrently, Adial secured $64 million in private placement financing, with $32 million upfront and potential for an additional $32 million upon Phase 1 initiation. The funds will advance AT177 through key clinical milestones, including IND-enabling studies and Phase 1...
06-11 15:43
